实盘配资

Be the most trusted biotech company

2026-06-26

Henlius’ Serplulimab Receives European Approval for a Fourth Indication, Expanding Its First-Line Treatment Footprint in Major High-Burden Cancers
2026-06-25

Henlius’ Proposed Ipilimumab Biosimilar HLX13 Completes First Patient Dosing in the U.S., Advancing Global Multicenter Clinical Development
2026-06-24

Organon CANADA and henlius Expand Access to Denosumab Treatments With LAUNCH OF BILDYOS® (Denosumab Injection) and TUZEMTY® (Denosumab Injection), Biosimilars to PROLIA and XGEVA
2026-06-23

Henlius’ Serplulimab Marks Third Publication in a Leading International Journal, with Small Cell Lung Cancer Long-Term Survival Data Published in JAMA Oncology and a 4-Year OS Rate of 21.9%
2026-06-17

STEAP1×CD3×CD28 Tri-specific TCE HLX3902 Receives China Clinical Approval, Promising Breakthrough in “Cold Tumour” Therapy
2026-06-17

Exploring Earlier-Stage Treatment Potential: Henlius’ Phase 2 Clinical Trial of HLX43 in Combination with Serplulimab for Neoadjuvant Treatment of NSCLC Approved for Clinical Trial in Australia
2026-06-16

Henlius Successfully Completes International Phase 3 Trial of HLX04-O for Ophthalmic Indication
2026-06-09

Henlius’ Serplulimab Approved for Perioperative Gastric Cancer, Pioneering a Chemotherapy-Sparring Adjuvant Approach
2026-06-05

Globalisation 2.0 | Henlius Advances Global Clinical Development of Pembrolizumab Biosimilar with First U.S. Patient Dosed